Illness script · Oncology

Tumor Lysis Syndrome

Metabolic emergency from massive tumor cell lysis releasing intracellular contents, causing hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia.

This illness script for Tumor Lysis Syndrome covers predisposing factors, classic presentation, mechanism, workup, management, and the clinical pivots that separate it from look-alikes—written for USMLE Step 1 and clerkship reasoning.

Updated Jul 19, 2026All scripts

01

Predisposing factors

  • High-grade hematologic malignancies: Burkitt lymphoma (highest risk), ALL, AML
  • Large tumor burden or rapidly proliferating tumors
  • Initiated by chemotherapy; rarely spontaneous
  • Pre-existing renal insufficiency or dehydration increases risk
  • Elevated baseline uric acid or LDH signals high risk

02

Presentation

  • Onset within 12–72 hours of chemotherapy initiation
  • Hyperkalemia → cardiac arrhythmias, weakness (most immediately life-threatening)
  • Hypocalcemia → tetany, seizures, Chvostek/Trousseau signs, QTc prolongation
  • Hyperuricemia → oliguria, flank pain, AKI
  • Nausea, vomiting, lethargy common early symptoms

03

Pathophysiology

  • Tumor cell lysis releases potassium, phosphate, nucleic acids, and proteins
  • Nucleic acids catabolized to uric acid → precipitates in renal tubules → AKI
  • Hyperphosphatemia chelates calcium → symptomatic hypocalcemia
  • Urate and calcium-phosphate crystal deposition worsens renal failure

04

Diagnostics

  • Cairo-Bishop criteria: ≥2 of hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia
  • Labs: BMP, uric acid, phosphate, LDH, CBC — monitor q6–8h in high-risk patients
  • ECG immediately if hyperkalemia suspected (peaked T waves, wide QRS)
  • Urinalysis may show urate crystals; urine output monitoring essential
  • LDH elevation correlates with tumor burden and TLS risk

05

Management

  • Aggressive IV hydration (2–3 L/m²/day) — cornerstone of prevention and treatment
  • Allopurinol for prophylaxis in intermediate-risk patients (blocks new uric acid synthesis)
  • Rasburicase for high-risk or established TLS — rapidly degrades existing uric acid
  • Treat hyperkalemia urgently (calcium gluconate, insulin/dextrose, kayexalate, dialysis if refractory)
  • Avoid calcium supplementation unless symptomatic hypocalcemia — worsens calcium-phosphate precipitation
  • Hemodialysis for refractory electrolyte abnormalities or severe AKI

06

Clinical pivots

How to separate this script from the look-alikes that show up on exams and on the wards.

  • Acute Kidney Injury (other causes)

    TLS has concurrent hyperuricemia + hyperkalemia + hyperphosphatemia + hypocalcemia in a chemo-treated cancer patient

  • Rhabdomyolysis

    Rhabdo has markedly elevated CK and myoglobinuria; no hyperphosphatemia-driven hypocalcemia pattern or uric acid surge

  • Addisonian crisis

    Addison's has hyponatremia + hyperkalemia but no hyperphosphatemia, hyperuricemia, or oncologic context

  • Spontaneous tumor lysis

    Same metabolic picture but occurs before chemo; rare, seen with Burkitt or bulky ALL — no cytotoxic trigger

View full library

Educational use only. This illness script is a study framework, not medical advice. Confirm decisions with current guidelines and your clinical supervisors.